Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of “Buy” by Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has received an average rating of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $25.60.

A number of analysts have recently weighed in on the company. Oppenheimer raised their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, December 10th.

Hedge Funds Weigh In On Astria Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATXS. Barclays PLC increased its holdings in shares of Astria Therapeutics by 70.5% in the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock valued at $1,020,000 after purchasing an additional 38,321 shares during the period. Wellington Management Group LLP boosted its position in Astria Therapeutics by 8.7% in the third quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 11,763 shares during the last quarter. RA Capital Management L.P. increased its holdings in Astria Therapeutics by 1.2% in the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after buying an additional 61,457 shares during the period. Redmile Group LLC acquired a new position in Astria Therapeutics in the 3rd quarter worth approximately $3,423,000. Finally, Patient Square Capital LP purchased a new position in Astria Therapeutics during the 3rd quarter worth approximately $434,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Down 2.0 %

Shares of ATXS opened at $9.36 on Thursday. The company has a 50 day moving average of $10.72 and a two-hundred day moving average of $10.70. Astria Therapeutics has a twelve month low of $5.88 and a twelve month high of $16.90. The company has a market cap of $528.22 million, a price-to-earnings ratio of -4.48 and a beta of 0.67.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.